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ABSTRACT
Objective: Peripheral inflammatory markers are elevated in patients with dementia. In order to
assess their etiologic role, we examined whether interleukin-6 (IL-6) and C-reactive protein
(CRP) measured in midlife predict concurrently assessed cognition and subsequent cognitive
decline.
Methods: Mean value of IL-6 and CRP, assessed on 5,217 persons (27.9% women) in 1991–
1993 and 1997–1999 in theWhitehall II longitudinal cohort study, were categorized into tertiles
to examine 10-year decline (assessments in 1997–1999, 2002–2004, and 2007–2009) in
standardized scores (mean 5 0, SD 5 1) of memory, reasoning, and verbal fluency using mixed
models. Mini-Mental State Examination (MMSE) was administered in 2002–2004 and 2007–
2009; decline $3 points was modeled with logistic regression. Analyses were adjusted for base-
line age, sex, education, and ethnicity; further analyses were also adjusted for smoking, obesity,
Framingham cardiovascular risk score, and chronic diseases (cancer, coronary heart disease,
stroke, diabetes, and depression).
Results: In cross-sectional analysis, reasoning was 0.08 SD (95% confidence interval [CI]20.14,
20.03) lower in participants with high compared to low IL-6. In longitudinal analysis, 10-year
decline in reasoning was greater (ptrend5 0.01) among participants with high IL-6 (20.35; 95%
CI 20.37, 20.33) than those with low IL-6 (20.29; 95% CI 20.31, 20.27). In addition, partic-
ipants with high IL-6 had 1.81 times greater odds ratio of decline in MMSE (95% CI 1.20, 2.71).
CRP was not associated with decline in any test.
Conclusions: Elevated IL-6 but not CRP in midlife predicts cognitive decline; the combined cross-
sectional and longitudinal effects over the 10-year observation period corresponded to an age
effect of 3.9 years. Neurology® 2014;83:486–493
GLOSSARY
CHD 5 coronary heart disease; CI 5 confidence interval; CRP 5 C-reactive protein; CVD 5 cardiovascular disease; IL-6 5
interleukin-6; IQR 5 interquartile range; MMSE 5 Mini-Mental State Examination.
Inflammatory molecules, including acute-phase inflammatory reactants and proinflammatory
cytokines, have been found in the CSF and b-amyloid plaques in patients with dementia.1–3
Inflammation appears to be a feature of dementia; amyloid deposition stimulates neuroinflam-
matory processes with neurotoxic effects that exacerbate neuronal damage. There is also evidence
that circulating levels of inflammatory markers are raised before clinical onset of dementia; for
instance, in persons without dementia, interleukin-6 (IL-6) and C-reactive protein (CRP) have
been shown to predict dementia.4–6 However, given the long preclinical phase of dementia,7 it is
unclear whether peripheral inflammation is a by-product of neuropathology or whether it
contributes to neuronal damage.
Evidence of an association between peripheral inflammatory markers and cognitive decline
rather than dementia, which represents the extreme clinical presentation of the pathologic
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process, would support an etiologic role for
inflammation in cognitive aging. To date, how-
ever, few prospective studies have examined
inflammatory markers in midlife as predictors
of cognitive decline. Here, we examine this asso-
ciation using 2 markers, IL-6 and CRP, expect-
ing IL-6 to have a stronger association with
cognition as it drives the production of down-
streammarkers such as CRP. As single measures
cannot reliably separate acute and chronic
inflammation and may therefore underestimate
associations with disease outcomes,8 we use the
mean of 2 measures taken 5 years apart to cap-
ture long-term inflammation. Our objective is
to examine the association of CRP and IL-6 in
midlife and cognitive decline over 10 years in a
large community-dwelling sample of men and
women.
METHODS The Whitehall II study is an ongoing cohort study
of men and women, originally employed by the British civil ser-
vice. The target population was all London-based office staff, aged
35–55 years. A total of 10,308 persons (6,895 men and 3,413
women), response rate 73%, were recruited to the study over
1985 to 1988.9 Since the baseline medical examination, follow-
up examinations have taken place approximately every 5 years:
1991–1993 (n 5 8,815); 1997–1999 (n 5 7,870); 2002–2004
(n 5 6,967); and 2007–2009 (n 5 6,761).
Standard protocol approvals, registrations, and patient
consents. Ethical approval for the Whitehall II study was
obtained from the University College London Medical School
committee on the ethics of human research (reference number
85/0938); all participants provided written informed consent.
Assessment of IL-6 and CRP. Fasting serum was collected
in 1991–1993 and 1997–1999 between 8 AM and 1 PM and
stored at 280°C. CRP was measured with a high-sensitivity
immunonephelometric assay in a BN ProSpec nephelometer
(Dade Behring, Milton Keynes, UK). IL-6 was measured with
a high-sensitivity ELISA (R&D Systems, Oxford, UK). Values
lower than the detection limit (0.15 mg/L for CRP, 0.08 pg/mL
for IL-6) were assigned a value equal to half the detection limit.
To measure short-term biological variation and laboratory error, a
repeat sample was taken from 150 participants for CRP and 241
participants for IL-6 at the 1991–1993 measure (average elapsed
time between samples, 32 days [SD 5 10.5 days]). Intra-assay
and interassay coefficients of variation were 4.7% and 8.3% for
CRP and 7.5% and 8.9% for IL-6.
Cognitive function. The cognitive test battery, administered at
3 clinical examinations over 10 years (1997–1999, 2002–2004,
and 2007–2009), was chosen to provide a comprehensive assess-
ment of cognitive function and be appropriate for this population
composed of individuals younger than in most studies on cogni-
tive aging.10 The tests included in the analysis had high test–retest
reliability, range 0.60–0.89, assessed on 556 participants who
were invited back to the clinic within 3 months of having taken
the test in 1997–1999.
Short-term verbal memory was assessed with a 20-word
free recall test. Participants were presented a list of 20 1- or
2-syllable words at 2-second intervals and were then asked to
recall in writing as many of the words as possible in any order with
2 minutes to do so.
The Alice Heim 4-I is composed of a series of 65 verbal and
mathematical reasoning items of increasing difficulty.11 It tests induc-
tive reasoning, measuring the ability to identify patterns and infer
principles and rules. Participants had 10 minutes to do this section.
We used 2 measures of verbal fluency, phonemic and seman-
tic, combined for the purposes of the analysis.12 Participants were
asked to recall in writing as many words beginning with S (pho-
nemic fluency) and as many animal names (semantic fluency) as
they could. One minute was allowed for each test; the observed
range on these tests was 0–35.
The Mini-Mental State Examination (MMSE),13 a brief
30-point measure of global cognitive function, was administered
at the last 2 waves of the cognitive data collection.
Covariates. Covariates included age, sex, ethnicity (white, south
Asian, black, other), and education, the highest qualification on
leaving full-time education (lower secondary school or less,
higher secondary school [usually achieved at age 18], university
or higher degree). Smoking status was reported by participants
and classified as never, ex, or current smoker. Obesity was
defined as body mass index $30 kg/m2.14 The Framingham
general cardiovascular disease (CVD) risk score was used to
assess subclinical disease, calculated using data on age, high-
density lipoprotein cholesterol, total cholesterol, systolic blood
pressure, cigarette smoking, and diabetes.15
The chronic diseases considered as covariates were coronary
heart disease (CHD); stroke, identified using hospital records data-
base; cancer, using the National Health Service cancer registry; and
diabetes, determined by oral glucose tolerance test (fasting glucose
$7.0 mmol/L, 2-hour postload glucose$11.1 mmol/L), reported
doctor-diagnosed diabetes, or use of diabetes medication.16 Antide-
pressant use was assessed using questions on medication. All par-
ticipants were followed for mortality using linkage to the national
mortality database.
Statistical analysis. All analyses were conducted using STATA
12. Participant characteristics were described as percentages or
mean (SD) when appropriate. Inflammatory markers were cate-
gorized into tertiles using mean values from 1991–1993 to
1997–1999. We also ran analyses using continuous scores, mod-
eled as an increment of 1 SD, after log transforming the inflam-
matory measures owing to skewed distributions. The association
of inflammatory markers with mortality over the follow-up was
examined using Cox proportional hazards models.
In order to allow comparison across cognitive tests, we stan-
dardized the raw scores of each test to z scores (mean 5 0;
SD 5 1). In the longitudinal analysis, the standardization to the
z score was carried out using the mean and SD from 1997 to 1999.
Linear mixed models17 were used to estimate the cross-sectional and
longitudinal association of inflammatory markers with cognition
(3 assessments, 1997–1999, 2002–2004, 2007–2009). Mixed
models use all available data over the follow-up, take into account
the fact that repeated measures on the same individual are corre-
lated with each other, and can handle missing data. In these anal-
yses, both the intercept and the slope were fitted as random effects,
allowing individuals to have different cognitive scores at baseline
and different rates of cognitive decline over the follow-up. The
intercept in these models yields the cross-sectional association and
the slope an estimate of the 10-year decline in cognitive scores and
the associated 95% confidence interval (CI). These analyses were
adjusted for sociodemographic characteristics (age, sex, ethnicity,
and education). In a further step, analyses were additionally
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adjusted for covariates associated with higher levels of inflammatory
markers (smoking, obesity, Framingham CVD risk, CHD, stroke,
cancer, diabetes, and antidepressant use).
The interaction term between sex, time, and inflammatory
markers suggested similar cognitive decline in men and women
(all p between 0.11 and 0.41), leading us to combine men and
women in the analysis. For both the baseline and the longitudinal
analysis, we tested for a linear trend as a function of tertiles of the
inflammatory markers. To allow interpretation of the regression
estimates of top vs bottom tertile of the inflammatory marker, we
compared them with the effect of age on cognition. The regres-
sion estimates were divided by the effect of 1 year increase in age
on cognition; the latter was calculated by regressing the standard-
ized 1997–1999 cognitive score on age.
In further analyses, we examined the association of the
inflammatory markers (mean value of measures taken in 1991–
1993 and 1997–1999) and decline in MMSE between 2002–
2004 and 2007–2009, modeled as a decline of 3 points or more.
These analyses were undertaken using logistic regression as the
distribution was highly skewed and unsuitable for linear regres-
sion. We compared the C-statistics of 2 predictive models for
decline in MMSE, one containing age and sex only and the other
additionally containing the inflammatory marker to assess its
incremental discriminative ability.
In sensitivity analyses, we used a Bonferroni-corrected critical
p value of 0.0125 (0.05/4) based on the fact that 4 cognitive tests
were used in the analysis (memory, reasoning, fluency, MMSE).
RESULTS A total of 7,666 (74.4%) of the original
10,308 participants of the Whitehall II study
participated in 1991–1993 and 1997–1999 waves of
data collection, when inflammatory markers were
assessed. Those with CRP values $10 mg/L (n 5
159 in 1991–1993 and n 5 197 in 1997–1999), an
indicator of acute infection, were removed from the
analysis. A total of 5,316 had valid data at both waves,
allowing mean values of IL-6 and CRP to be calculated
(figure). A total of 212 deaths were recorded over the
cognitive follow-up and 1 SD higher CRP (1.25, 95%
CI 1.07, 1.47) and IL-6 (1.27, 95% CI 1.11, 1.45)
were associated with greater hazard ratio of mortality.
Subsequent analyses were undertaken on 5,217
participants with cognitive data over the follow-up.
Approximately 72% had cognitive data at all 3 waves
and 18% at 2 waves. Compared to individuals not
included in these analyses, the analytic samples
consisted of younger participants (55.7 vs 56.4 years,
p, 0.001), more men (72.1% vs 61.6%, p, 0.001),
and more educated individuals (30.4% vs 23.8% had a
university degree, p , 0.001).
The median for IL-6 was 1.43 pg/mL (interquartile
range [IQR] 1.07, 1.99), based on assessments in
1991–1993 (1.41 pg/mL) and 1997–1999 (1.42 pg/
mL, correlation r 5 0.47); the corresponding median
was 0.98 mg/L for CRP (IQR 0.52, 1.94, first and
second assessments 0.89 mg/mL and 1.02 mg/L,
Figure Study profile
CRP 5 C-reactive protein.
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respectively, correlation r5 0.61). Changes in inflam-
matory marker levels between the 2 assessments were
not associated with cognitive tests (all r # 0.03), lead-
ing us not to examine them further. The inflammatory
markers, averaged over 2 assessments, were moderately
correlated with each other (rs5 0.49, p, 0.001). One
year greater age was associated with20.040 SD lower
memory,20.036 lower reasoning, and 20.043 lower
verbal fluency, all p, 0.0001. Table 1 presents sample
characteristics as a function of the tertiles of IL-6 and
CRP. Both markers were associated with all baseline
covariates, except stroke; CRP was also not associated
with cancer.
In cross-sectional analyses (table 2), adjusted for
sociodemographic measures, those in the highest IL-6
tertile had poorer cognitive scores on all tests, the dif-
ference compared to those in the lowest tertile ranging
from20.08 to20.13 of an SD—corresponding to an
age effect of 2.0 years for memory, 2.2 years for reason-
ing, and 3.0 years for verbal fluency. Those in the inter-
mediate and high tertile of CRP had lower scores in
reasoning (20.09; 95% CI 20.14, 20.04). Adjust-
ment for the full set of covariates (table e-1 on the
Neurology® Web site at Neurology.org) attenuated
associations with memory but higher IL-6 remained
associated with poorer scores on reasoning and fluency
and higher CRP levels with poorer scores on reasoning.
In longitudinal analyses, a decline over 10 years
of approximately one-third of a baseline SD was
observed on all tests (table 3). Compared to the
lowest IL-6 tertile (20.29, 95% CI 20.31,
20.27), those in the intermediate (20.32, 95% CI
20.35, 20.30; p , 0.05) and highest (20.35, 95%
CI 20.37, 20.33, p , 0.001) tertiles experienced
faster decline in reasoning. The difference in decline
in reasoning between the highest and lowest IL-6
tertile corresponded to an age effect of 1.7 years.
The decline in the highest tertile remained statisti-
cally significant when adjusted for the full range of
covariates (table e-2). CRP in the highest tertile was
also associated with faster decline in reasoning (table
3) but adjustment for all covariates rendered the
difference nonsignificant (table e-2).
Table 4 shows the association of the inflammatory
markers with decline of$3 points (n5 191, 4.7%) in
MMSE scores between 2002–2004 and 2007–2009.
Those in the highest IL-6 tertile were 1.85 (95% CI
1.25, 2.73) times more likely to register decline in
MMSE than those in the lowest tertile. This greater
likelihood of decline in the highest IL-6 category re-
mained in the fully adjusted model (odds ratio 1.81;
95%CI 1.20, 2.71; model 6). The associations of CRP
with decline in MMSE did not reach statistical signif-
icance. The change in C-statistics suggested that IL-6
(from 0.666 to 0.684, p 5 0.05) but not CRP (from
0.666 to 0.671, p 5 0.32) improves discriminative
ability in prediction of decline in MMSE.
The cross-sectional and longitudinal associations
between IL-6 and reasoning (tables 2–4) remained
statistically significant after Bonferroni correction
Table 1 Baseline (1997–1999) correlates of IL-6 and CRPa
IL-6 (tertile)a CRP (tertile)a
Low
(<1.18 pg/mL)
Intermediate
(1.18–1.75 pg/mL)
High
(‡1.75 pg/mL) pb
Low
(<0.65 mg/L)
Intermediate
(0.65–1.48 mg/L)
High
(‡1.48 mg/L) pb
N 1,729 1,742 1,746 1,737 1,739 1,741
Age, y, mean (SD) 54.0 (5.6) 55.9 (6.0) 57.2 (6.1) ,0.001 54.8 (5.9) 55.8 (6.0) 56.5 (6.2) ,0.001
Male, % 75.0 73.2 68.2 ,0.001 74.5 74.4 67.4 ,0.001
High education, % 36.2 29.7 24.2 ,0.001 35.5 28.6 26.0 ,0.001
White, % 95.8 92.7 87.3 ,0.001 93.9 92.3 89.5 ,0.001
Current smoker, % 5.3 8.5 13.6 ,0.001 5.8 8.0 13.7 ,0.001
Obesity,c % 4.3 10.9 22.9 ,0.001 3.1 11.0 24.0 ,0.001
Antidepressants, % 2.7 2.5 3.3 0.02 2.1 2.8 3.6 ,0.001
Framingham CVD risk,
mean (SD)
9.2 (6.2) 12.1 (8.2) 14.8 (10.2) ,0.001 9.7 (6.8) 12.1 (8.2) 14.3 (10.0) ,0.001
Coronary heart disease, % 3.9 5.7 8.3 ,0.001 3.3 6.3 8.3 ,0.001
Stroke, % 0.4 0.3 0.6 0.37 0.5 0.4 0.4 0.87
Diabetes, % 2.5 4.6 7.6 ,0.001 2.4 4.5 7.9 ,0.001
Cancer, % 2.2 3.3 4.1 0.01 3.2 2.8 3.8 0.27
Abbreviations: CRP 5 C-reactive protein; CVD 5 cardiovascular disease; IL-6 5 interleukin-6.
a Tertiles based on average of measures taken in 1991–1993 and 1997–1999.
bp for trend.
cUsing World Health Organization recommendations.
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for 4 tests; this was also the case for IL-6 and decline
in MMSE.
DISCUSSION Our results, based on participants aged
56 years at the start of cognitive testing, suggest that
inflammatory markers are associated with cognition, in
both cross-sectional and longitudinal associations.
Three features qualify these findings. First, memory
had no strong association with the inflammatory
markers. Second, of the 2 markers examined, IL-6 had
a more robust association with cognition. Third,
although the cross-sectional effects were stronger,
the longitudinal effects were nevertheless present,
suggesting that midlife inflammation is related to
cognitive decline. The effects may appear small but
over the 10-year observation period the combined
effect using both cross-sectional and longitudinal effects
corresponds to an age effect of 3.9 years for reasoning.
Previous studies on the association between inflam-
mation and cognitive decline are inconsistent. Some
studies show no association18–20 and others show greater
decline in those with higher inflammation.21–24 How-
ever, much of the evidence is based on older adults,
where preclinical dementia cannot be ruled out. No
previous study to our knowledge has used repeated
measures of inflammatory markers to correct for
within-person fluctuations in inflammatory markers
in analysis with cognitive outcomes. Memory appears
not to be one of the domains affected by long-term
inflammation in our analysis. Previous cross-sectional
studies report associations with multiple cognitive do-
mains25; the longitudinal studies used either a global
measure, such as the MMSE,21 or combined tests to
produce global scores.24 All the tests used in the present
analyses have been shown previously to be sensitive to
age-related changes in cognition in midlife.10 Timed
tests of reasoning, such as the Alice Heim test, are good
measures of processing speed or mental efficiency.26
Further support for the lack of association with mem-
ory comes from studies showing greater effects
of inflammatory factors on vascular rather than
Alzheimer-type dementia.6,27
Previous studies on the association between
inflammatory markers and cognitive outcomes have
not been conclusive on the specific marker that may
be of special interest. In the Rotterdam Study, IL-6
but not CRP was associated with an increased risk
of dementia.4 In relation to cognition, some studies
report associations with CRP but not IL-6,28 others
with IL-6 but not CRP,23 and some find both to be
associated with cognition.12 However, neuroimaging
studies show consistently stronger associations
with IL-6 than with CRP.29–31 IL-6 is a major proin-
flammatory cytokine, produced in a variety of tissues,
and CRP is a downstream product of the acute phase
response, derived via IL-6-dependent hepatic
Table 2 Cross-sectional association between IL-6 and CRP (mean of measures in 1991–1993 and 1997–1999) and cognitive function
(1997–1999)
Inflammatory markers N Memory, b (95% CI) p
Reasoning (AH4-I),
b (95% CI) p
Verbal fluency,a
b (95% CI) p
IL-6, pg/mL (tertile)b
<1.18 1,729 0.00 (Ref) 0.00 (Ref) 0.00 (Ref)
1.18–1.74 1,724 20.05 (20.11, 0.01) 0.12 20.01 (20.07, 0.04) 0.59 0.01 (20.04, 0.07) 0.65
‡1.75 1,746 20.08 (20.14, 20.01)c 0.016 20.08 (20.14, 20.03)d 0.002 20.13 (20.19, 20.07)e ,0.0001
p for trend 0.01 0.002 ,0.001
Log-transformed IL-6
(per 1 SD increment)
5,217 20.03 (20.05, 20.00)c 0.028 20.03 (20.06, 20.01)d 0.002 20.04 (20.06, 20.01)d 0.002
CRP, mg/L (tertile)b
<0.65 1,737 0.00 (Ref) 0.00 (Ref) 0.00 (Ref)
0.65–1.47 1,739 20.04 (20.10, 0.02) 0.17 20.09 (20.14, 20.04)e ,0.0001 20.04 (20.10, 0.01) 0.13
‡1.48 1,741 20.05 (20.11, 0.01) 0.11 20.09 (20.14, 20.04)e 0.001 20.05 (20.11, 0.00) 0.09
p for trend 0.10 ,0.001 0.09
Log-transformed CRP
(per 1 SD increment)
5,217 20.03 (20.05, 20.00)c 0.035 20.03 (20.05, 20.01)d 0.008 20.02 (20.04, 0.00) 0.12
Abbreviations: AH4-I 5 Alice Heim 4-I; CI 5 confidence interval; CRP 5 C-reactive protein; IL-6 5 interleukin-6; Ref 5 reference.
Regression coefficients (b and 95% CIs) estimates from linear mixed models that assess cross-sectional and longitudinal associations simultaneously.
Analysis adjusted for age, sex, ethnicity, and education.
aComposed of a test of semantic (animal words) and phonemic (S words) fluency.
b Tertiles based on average of measures taken in 1991–1993 and 1997–1999.
cp , 0.05.
dp , 0.01.
ep , 0.001.
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biosynthesis and secretion into the systemic circula-
tion.32 Thus, IL-6 might be a more sensitive and
appropriate marker for a study of inflammation and
cognition.
Brains of patients with dementia have activated
microglia, inflammatory factors, and high circulating
inflammatory markers. However, at least one previ-
ous study suggests that reverse causation is an unlikely
Table 4 Association between IL-6 and CRP (mean of measures in 1991–1993 and 1997–1999) and decline of 3 points or more in MMSE
(2002–2004, 2007–2009)
Inflammatory markers
Model 1,
OR (95% CI)
Model 2,
OR (95% CI)
Model 3,
OR (95% CI)
Model 4,
OR (95% CI)
Model 5,
OR (95% CI)
Model 6,
OR (95% CI)
IL-6, pg/mL (tertile)a
<1.18 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
1.18–1.74 1.26 (0.83, 1.90) 1.25 (0.83, 1.88) 1.28 (0.85, 1.94) 1.22 (0.81, 1.85) 1.26 (0.83, 1.89) 1.24 (0.82, 1.88)
‡1.75 1.85 (1.25, 2.73)b 1.80 (1.21, 2.66)b 1.96 (1.31, 2.91)c 1.73 (1.16, 2.58)b 1.83 (1.23, 2.71)b 1.81 (1.20, 2.71)b
p for trend 0.001 0.002 0.001 0.005 0.002 0.003
CRP, mg/L (tertile)a
<0.65 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
0.65–1.47 1.19 (0.81, 1.73) 1.18 (0.81, 1.72) 1.21 (0.83, 1.77) 1.14 (0.78, 1.67) 1.18 (0.81, 1.73) 1.17 (0.79, 1.71)
‡1.48 1.34 (0.92, 1.95) 1.30 (0.89, 1.89) 1.40 (0.96, 2.06) 1.23 (0.83, 1.80) 1.32 (0.91, 1.92) 1.26 (0.85, 1.87)
p for trend 0.12 0.18 0.08 0.30 0.15 0.25
Abbreviations: CI 5 confidence interval; CRP 5 C-reactive protein; IL-6 5 interleukin-6; MMSE 5 Mini-Mental State Examination; OR 5 odds ratio;
Ref 5 reference.
Model 1: analysis adjusted for age, sex, ethnicity, and education; model 2: model 1 1 smoking; model 3: model 1 1 obesity; model 4: model 11 Framingham
cardiovascular disease risk score; model 5: model 1 1 coronary heart disease, stroke, cancer, diabetes, antidepressant use; model 6: all covariates. Total
n 5 4,057, decline in MMSE score $3 points: n 5 191.
a Tertiles based on average of measures taken in 1991–1993 and 1997–1999.
bp , 0.01.
cp , 0.001.
Table 3 Association between IL-6 and CRP (mean of measures in 1991–1993 and 1997–1999) and cognitive decline (1997–1999, 2002–
2004, 2007–2009)
Inflammatory markers N Memory, b (95% CI) p
Reasoning (AH4-I),
b (95% CI) p
Verbal fluency,a
b (95% CI) p
IL-6, pg/mL (tertile)b
<1.18 1,729 20.30 (20.34, 20.26) 20.29 (20.31, 20.27) 20.38 (20.41, 20.35)
1.18–1.74 1,724 20.27 (20.31, 20.23) 0.26 20.32 (20.35, 20.30)c 0.047 20.39 (20.42, 20.36) 0.71
‡1.75 1,746 20.30 (20.34, 20.25) 0.96 20.35 (20.37, 20.33)d 0.001 20.37 (20.40, 20.33) 0.48
p for trend 0.99 0.001 0.59
Log-transformed IL-6
(per 1 SD increment)
5,217 20.01 (20.03, 0.01) 0.44 20.02 (20.03, 20.00)c 0.037 20.00 (20.02, 0.02) 0.83
CRP, mg/L (tertile)b
<0.65 1,737 20.28 (20.32, 20.24) 20.32 (20.34, 20.29) 20.36 (20.39, 20.33)
0.65–1.47 1,739 20.29 (20.33, 20.24) 0.84 20.30 (20.32, 20.27) 0.25 20.38 (20.41, 20.35) 0.49
‡1.48 1,741 20.29 (20.34, 20.25) 0.61 20.35 (20.37, 20.33)c 0.044 20.40 (20.43, 20.37) 0.08
p for trend 0.64 0.05 0.09
Log-transformed CRP
(per 1 SD increment)
5,217 0.00 (20.02, 0.02) 0.82 20.02 (20.03, 20.00)c 0.020 20.01 (20.03, 0.00) 0.09
Abbreviations: AH4-I 5 Alice Heim 4-I; CI 5 confidence interval; CRP 5 C-reactive protein; IL-6 5 interleukin-6.
Regression coefficients (b and 95% CIs) estimates from linear mixed models that assess cross-sectional and longitudinal associations simultaneously.
Analysis adjusted for age, sex, ethnicity, and education.
aComposed of a test of semantic (animal words) and phonemic (S words) fluency.
b Tertiles based on average of measures taken in 1991–1993 and 1997–1999.
cp , 0.05.
dp , 0.001.
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explanation of the association between peripheral
inflammatory markers and dementia. CRP was as-
sessed in the Honolulu Aging Study 25 years prior
to the assessment of dementia and those with higher
levels of CRP had greater risk of dementia.33 Elevated
levels of peripheral inflammatory markers are not sim-
ply a consequence of dementia-related processes;
infection, trauma, ischemia, or accumulation of lipids
can trigger inflammatory responses.34 Inflammatory
markers might influence cognition through their pro-
thrombotic effects35; they are thought to be involved
in atherothrombotic vascular events as suggested by
their association with silent brain infarction.36
Our findings need to be considered in light of
study strengths and limitations. A key strength of
the study is the use of 2 measures of each inflamma-
tory marker taken 5 years apart, prior to cognitive
testing in order to better account for within-person
variability and measurement error. The age range of
the participants (45–69 at the start of cognitive test-
ing) is a strength as the results are unlikely to
be minimally if at all affected by preclinical dementia.
A further strength is the use of appropriate statistical
methodology to model change. Many studies21,23,24
showing inflammatory markers to predict cognitive
decline adjusted inappropriately for the baseline cog-
nitive score.
Limitations of our study include the lack of socio-
economic and ethnic diversity in the population; all
participants were in stable employment at study
inception, thus were not fully representative of the
general population. A further limitation is the use
of only 2 serologic markers of systemic inflammation.
Although CRP and IL-6 are widely measured, it re-
mains unclear whether there are more relevant
markers of peripheral inflammation in relation to cog-
nitive function. Finally, the categorization of the
inflammatory markers and decline in MMSE is arbi-
trary and further research is needed to find clinically
relevant cutoffs in nonelderly populations.
Taken together, although much recent effort has
been directed at understanding the role of abnormal
amyloid metabolism for dementia, multiple factors
are likely to be involved in cognitive aging. Inflamma-
tion is likely to play a role because of its impact on
cerebral small-vessel disease, which could lead to
changes that affect cognitive ageing.37 The use of non-
steroidal anti-inflammatory drugs (naproxen or cele-
coxib) in the Alzheimer’s Disease Anti-Inflammatory
Prevention Trial was found not to improve cognitive
function in older adults38 but recent reanalysis
of those data suggests a beneficial role of anti-
inflammatory drugs in the early, asymptomatic phases
of the dementia.39 The finding of elevations in proin-
flammatory cytokine production during early middle
age in persons with a family history of Alzheimer
disease40 also suggests a role for inflammation in cog-
nition. Our findings do not establish causality but
suggest that peripheral inflammation in midlife might
influence cognitive aging.
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